



ATTORNEY DOCKET NO. 03225.0001U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
Poynard)	Art Unit: Unassigned
)	
Application No. 10/650,260)	Examiner: Unassigned
)	
Filing Date: August 27, 2003)	Confirmation No. Unassigned
)	
For: DIAGNOSIS METHOD OF)	
INFLAMMATORY, FIBROTIC OR)	
CANCEROUS DISEASE USING)	
BIOCHEMICAL MARKERS)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Form PTO-1449 is a listing of documents known to Applicants and/or their attorneys. The documents marked with an asterisk (*) were cited by or submitted to the Patent Office in U.S. Application No. 09/687,459, filed October 13, 2000, to which the present application claims priority. Pursuant to 37 C.F.R. § 1.98(d), copies of these documents are not enclosed.

ATTORNEY DOCKET NO. 03225.0001U2
Application No. 10/650,260


This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(1) and (3) in that this Information Disclosure Statement is being filed within three months of the filing date of the present patent application, and a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed to be due; however, the Commissioner is hereby authorized to charge any fees which may be required or to credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.


Gwendolyn D. Spratt
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.


Gwendolyn D. Spratt

10-3-03
Date



Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**LIST OF INFORMATION CITED BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/650,260
Filing Date	August 27, 2003
First Named Inventor	Poynard
Group Art Unit	Unassigned
Examiner Name	Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	*A1	5,935,798	08/10/1999	Price et al.	435	7.23	
	*A2	4,312,853	01/26/1982	Timpl	424	1	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
	*A3	EP 0 911 343 A2	04/28/1999	Tosoh Corporation	
	*A4	WO 01/86304 A2	11/15/2001	Bayer Aktiengesellschaft	

NON-PATENT DOCUMENTS

Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	*A5	Bedossa et al., "Apolipoprotein AI is a Serum and Tissue Marker of Liver Fibrosis in Alcoholic Patients." <i>Alcohol Clin. Exp. Res.</i> 13(6):829-833 (November/December 1989)
	*A6	Gabrielli et al., "Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis." <i>Clin. Chim. Acta</i> 265:21-31 (1997)
	*A7	Guechot et al., "Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis." <i>Clin Chem.</i> 42(4):558-563 (1996)
	*A8	Johnston, "Special Considerations in Interpreting Liver Function Tests." <i>Am. Fam. Physician</i> pp. 1-11 (April 15, 1999) www.aafp.org/afp/990415ap/2223.html (Print Date of February 8, 2002)
	*A9	Kasahara et al., "Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response." <i>J. Hepatol.</i> 26(3):574-583 (March 1997)
	*A10	Kropf et al., "Efficacy of Serum Laminin Measurement for Diagnosis of Fibrotic Liver Diseases." <i>Clin. Chem.</i> 34(10):2026-2030 (1988)
	*A11	Naveau et al., "Alpha-2-Macroglobulin and Hepatic Fibrosis. Diagnostic Interest." <i>Dig. Dis. Sci.</i> 39(11):2426-2432 (November 1994)
	*A12	Oberti et al., "Noninvasive Diagnosis of Hepatic Fibrosis or Cirrhosis." <i>Gastroenterology</i> 113(5):1609-1616 (November 1997)
	*A13	Pilette et al., "Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers." <i>J. Hepatol.</i> 28(3):439-446 (March 1998)
	*A14	Poynard and Bedossa, "Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus." METAVIR and CLINIVIR Cooperative Study Groups. <i>J. Viral Hepat.</i> 4(3):199-208 (May 1997)



	*A15	Poynard et al., "Natural history of liver fibrosis progression in patients with chronic hepatitis C." The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups. <i>Lancet</i> 349(9055):825-832 (March 22, 1997)
	*A16	Teare et al., "Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis." <i>Lancet</i> 342:895-898 (October 9, 1993)
	*A17	Wong et al., "Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection." <i>J. Viral Hepat.</i> 5:187-192 (May 1998)
Examiner Signature:		Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		